Skip to main content

Table 1 Patient demographics, baseline disease, and clinical characteristics

From: Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

  Standard cytogenetic riska High cytogenetic riska,b
Characteristic D-Vd (n = 141) Vd (n = 140) D-Vd (n = 40) Vd (n = 35)
Age, years
 Median (range) 64 (40–88) 64 (33–85) 63 (37–79) 59 (37–81)
 ≥ 75 years, n (%) 9 (6) 20 (14) 4 (10) 5 (14)
Sex, n (%)
 Male 79 (56) 89 (64) 22 (55) 18 (51)
Race, n (%)
 White 123 (87) 123 (88) 33 (83) 31 (89)
 Black or African American 9 (6) 2 (1) 1 (3) 1 (3)
 Asian 8 (6) 8 (6) 4 (10) 2 (6)
 Native Hawaiian or other Pacific Islander 1 (1) 0 0 0
 Other 0 1 (1) 0 0
 Unknown/not reported 0 6 (4) 2 (5) 1 (3)
ISS stage, n (%)c
 I 48 (34) 55 (39) 22 (55) 14 (40)
 II 57 (40) 56 (40) 11 (28) 16 (46)
 III 36 (26) 29 (21) 7 (18) 5 (14)
ECOG performance status score, n (%)
 0 54 (38) 64 (46) 16 (40) 15 (43)
 1 78 (55) 62 (44) 22 (55) 19 (54)
 2 9 (6) 14 (10) 2 (5) 1 (3)
Cytogenetic profile, n (%)a,b
 t(4;14) 13 (33) 15 (43)
 t(14;16) 4 (10) 5 (14)
 del17p 27 (68) 20 (57)
 ≥ 2 risk factorsd 4 (10) 4 (11)
Median (range) time from diagnosis, years 4.3 (0.7–20.7) 3.6 (0.6–18.6) 3.3 (1.0–10.5) 3.7 (1.0–14.8)
Prior lines of therapy, n (%)
 1 70 (50) 67 (48) 21 (53) 12 (34)
 2 32 (23) 40 (29) 11 (28) 15 (43)
 3 25 (18) 16 (11) 5 (13) 6 (17)
 > 3 14 (10) 17 (12) 3 (8) 2 (6)
 Median (range) 2 (1–9) 2 (1–10) 1 (1–6) 2 (1–4)
Prior ASCT, n (%) 90 (64) 79 (56) 27 (68) 21 (60)
Prior PI, n (%) 101 (72) 94 (67) 27 (68) 28 (80)
 Bortezomib 98 (70) 89 (64) 25 (63) 26 (74)
Prior IMiD, n (%) 104 (74) 110 (79) 28 (70) 29 (83)
 Lenalidomide 52 (37) 66 (47) 15 (38) 17 (49)
Prior PI + IMiD, n (%) 73 (52) 67 (48) 15 (38) 22 (63)
Refractory to PI only, n (%) 1 (1) 2 (1) 2 (5) 1 (3)
Refractory to IMiD only, n (%) 41 (29) 51 (36) 12 (30) 11 (31)
Refractory to PI and IMiD, n (%) 6 (4) 2 (1) 0 4 (11)
Refractory to last line of therapy, n (%) 40 (28) 48 (34) 11 (28) 14 (40)
  1. D-Vd daratumumab/bortezomib/dexamethasone, Vd bortezomib/dexamethasone, ISS International Staging System, ECOG Eastern Cooperative Oncology Group, ASCT autologous stem cell transplantation, PI proteasome inhibitor, IMiD immunomodulatory drug, FISH fluorescence in situ hybridization
  2. Note: percentages may not equal 100% due to rounding
  3. aBased on FISH/karyotype testing
  4. bPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality
  5. cISS stage is derived based on the combination of serum β2-microglobulin and albumin
  6. dPatients with ≥ 2 of the t(4;14), t(14;16), or del17p risk factors